Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID (32194151)
Authors Grellety T, Peyraud F, Sevenet N, Tredan O, Dohollou N, Barouk-Simonet E, Kind M, Longy M, Blay JY, Italiano A
Title Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA.
Journal Annals of oncology : official journal of the European Society for Medical Oncology
Vol 31
Issue 6
Date 2020 06
URL
Abstract Text

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
PALB2 Y551* PALB2 S859* Her2-receptor negative breast cancer predicted - sensitive Olaparib Case Reports/Case Series Actionable In a clinical case study, a patient with metastatic hormone receptor (ESR1/PGR)-positive, ERBB2 (HER2)-negative breast cancer harboring PALB2 Y551* and S859* who progressed on prior therapies achieved a partial response to Lynparza (olaparib) treatment after 3 months and a 70% decrease in tumor burden at 6 months (PMID: 32194151). 32194151